Commons, Marty

WRN inhibitors represent a fast-emerging precision oncology segment targeting DNA repair vulnerabilities in microsatellite instability-high (MSI-H) tumors through synthetic lethality mechanisms.

Quetzal Therapeutics officially launched with $50 million in committed capital to develop transformative therapies for rare and life-threatening diseases.

Biomerica has appointed Scott Madel as Chief Commercial Officer to accelerate commercialization of its inFoods IBS diagnostic test, bringing over 20 years of experience in laboratory testing and clinical diagnostics.

DelveInsight's 2025 pipeline report reveals over 20 companies actively developing more than 20 innovative therapies for HER2-positive gastric cancer treatment.

The first patient worldwide has been treated with Remibrutinib, a novel B-cell targeting therapy for Myasthenia Gravis, marking the start of an international Phase III clinical trial at HonorHealth Research Institute.

Protara Therapeutics has appointed William Conkling as Chief Commercial Officer, bringing over two decades of experience in developing and commercializing cancer and rare disease therapeutics.

DelveInsight's 2025 pipeline report reveals over 10 pharmaceutical companies are actively developing 12+ therapies for neurofibromatoses treatment across various clinical stages.

• The schizophrenia market is expected to grow significantly, driven by the launch of novel therapies and increased diagnosis rates. • Long-acting injectables (LAIs) are gaining traction despite higher costs, offering an alternative to oral antipsychotics. • The US dominates the schizophrenia market due to a large patient population and high drug costs. • Emerging treatments like Cobenfy, evenamide, Ingrezza, and iclepertin aim to address unmet needs in managing both positive and negative symptoms.

Alpelisib combined with fulvestrant demonstrates notable activity in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced breast cancer after CDK4/6 inhibitor and aromatase inhibitor failure.

• Final results from the phase II GEOMETRY mono-1 trial reinforce capmatinib's effectiveness in treating NSCLC patients with MET exon 14 skipping mutations. • In treatment-naive patients, capmatinib achieved a 68% objective response rate and a median overall survival of 21.4 months. • Previously treated patients experienced a 44% objective response rate and a median overall survival of 16.8 months with capmatinib. • The study confirms MET exon 14 skipping as a targetable oncogenic driver, supporting capmatinib as a viable treatment option.